# Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer

> **NCT05628610** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 130 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Tislelizumab
- **RADIATION:** Radiation
- **DRUG:** Paclitaxel
- **DRUG:** Platinum: cisplatin, carboplatin, naidaplatin and other platinum drugs

## Key facts

- **NCT ID:** NCT05628610
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2024-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05628610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05628610, "Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05628610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*